Pharmaceutical

Lilly bolsters IBD portfolio with $3.2bn Morphic acquisition

Morphic’s lead asset MORF-057 is being investigated in three IBD clinical trials, with data in ulcerative colitis expected next year.

Jul 10, 2024 - 04:00
Lilly bolsters IBD portfolio with $3.2bn Morphic acquisition
Morphic’s lead asset MORF-057 is being investigated in three IBD clinical trials, with data in ulcerative colitis expected next year.
Read the original article

Tags:

Previous Article

Moderna and Mitsubishi Tanabe link on mRNA vaccines in Japan

Next Article

UK pharma group reprimands Novo Nordisk for undisclosed payments

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

J&J signs Stelara biosimilar settlement deal with Formycon and Fresenius

J&J signs Stelara biosimilar settlement deal with Formy...

Aug 8, 2023

Activist investor Starboard cries foul play in exec U-turn at Pfizer

Activist investor Starboard cries foul play in exec U-t...

Oct 12, 2024

Which drugs are most likely to be approved in Tenosynov...

Mar 28, 2024